Crossmark

Outcomes of capecitabine plus temozolomide combination therapy in patients with advanced or metastatic pancreatic neuroendocrine tumors: a retrospective observational single-center study

Crossref DOI link: https://doi.org/10.1007/s10147-025-02779-1

Published Online: 2025-05-09

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hibino, Yukiko

Hijioka, Susumu https://orcid.org/0000-0002-0394-6876
Morizane, Chigusa

Agarie, Daiki

Okamoto, Kohei

Yamashige, Daiki

Yagi, Shin

Fukuda, Soma

Kuwada, Masaru

Komori, Yasuhiro

Okada, Mao

Maruki, Yuta

Nagashio, Yoshikuni

Ueno, Hideki

Okusaka, Takuji
License Information

Text and Data Mining valid from 2025-05-09

Version of Record valid from 2025-05-09
More Information

Article History

Received: 11 September 2024

Accepted: 29 April 2025

First Online: 9 May 2025

Declarations

:

: Susumu Hijioka has received honoraria from Teijin Pharma and Novartis. The other authors declare no conflict of interests for this article.

Document is current

Any future updates will be listed below